149 related articles for article (PubMed ID: 26647959)
1. NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression.
Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
Int J Oncol; 2016 Jan; 48(1):225-34. PubMed ID: 26647959
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer.
Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
Oncol Rep; 2016 Mar; 35(3):1549-56. PubMed ID: 26717965
[TBL] [Abstract][Full Text] [Related]
3. Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner.
Sun Y; Guan Z; Zhao W; Jiang Y; Li Q; Cheng Y; Xu Y
Int J Oncol; 2017 Oct; 51(4):1219-1226. PubMed ID: 28791405
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
Ito Y; Kikuchi E; Tanaka N; Kosaka T; Suzuki E; Mizuno R; Shinojima T; Miyajima A; Umezawa K; Oya M
BMC Cancer; 2015 Apr; 15():324. PubMed ID: 25926105
[TBL] [Abstract][Full Text] [Related]
5. TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling.
Tan ST; Liu SY; Wu B
Cancer Res Treat; 2016 Oct; 48(4):1302-1312. PubMed ID: 26987391
[TBL] [Abstract][Full Text] [Related]
6. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
[TBL] [Abstract][Full Text] [Related]
7. RelB sustains endocrine resistant malignancy: an insight of noncanonical NF-κB pathway into breast Cancer progression.
Wang M; Zhang Y; Xu Z; Qian P; Sun W; Wang X; Jian Z; Xia T; Xu Y; Tang J
Cell Commun Signal; 2020 Aug; 18(1):128. PubMed ID: 32807176
[TBL] [Abstract][Full Text] [Related]
8. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
10. miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression.
Cui X; Kong C; Zhu Y; Zeng Y; Zhang Z; Liu X; Zhan B; Piao C; Jiang Z
Oncotarget; 2016 Jul; 7(30):48547-48561. PubMed ID: 27391066
[TBL] [Abstract][Full Text] [Related]
11. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
12. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
[TBL] [Abstract][Full Text] [Related]
13. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells.
Liu J; Bi J; Li Z; Li Z; Liu X; Kong C
Int J Mol Med; 2018 Mar; 41(3):1765-1773. PubMed ID: 29328435
[TBL] [Abstract][Full Text] [Related]
14. Ursolic acid induces apoptosis via Akt/NF-κB signaling suppression in T24 human bladder cancer cells.
Gai L; Cai N; Wang L; Xu X; Kong X
Mol Med Rep; 2013 May; 7(5):1673-7. PubMed ID: 23483134
[TBL] [Abstract][Full Text] [Related]
15. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9.
Gao Y; Guan Z; Chen J; Xie H; Yang Z; Fan J; Wang X; Li L
Int J Oncol; 2015 Aug; 47(2):690-700. PubMed ID: 26058729
[TBL] [Abstract][Full Text] [Related]
16. Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-κB signaling activation.
Guan Z; Sun Y; Mu L; Jiang Y; Fan J
BMC Cancer; 2022 Mar; 22(1):240. PubMed ID: 35246056
[TBL] [Abstract][Full Text] [Related]
17. Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells, as well as the activation of AKT and ERK pathway.
Li C; Su H; Ruan C; Li X
Folia Histochem Cytobiol; 2021; 59(1):40-48. PubMed ID: 33577073
[TBL] [Abstract][Full Text] [Related]
18. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
Huang Y; Luan T; Bao X; Fu S; Li N; Li H; Wang H; Li C; Wang J
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850704
[TBL] [Abstract][Full Text] [Related]
19. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
Kim JK; Kim KD; Lee E; Lim JS; Cho HJ; Yoon HK; Cho MY; Baek KE; Park YP; Paik SG; Choe YK; Lee HG
Cancer Lett; 2004 Aug; 212(1):61-70. PubMed ID: 15246562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
